2024
Estimates of intra-cluster correlation coefficients from 2018 USA Medicare data to inform the design of cluster randomized trials in Alzheimer’s and related dementias
Ouyang Y, Li F, Li X, Bynum J, Mor V, Taljaard M. Estimates of intra-cluster correlation coefficients from 2018 USA Medicare data to inform the design of cluster randomized trials in Alzheimer’s and related dementias. Trials 2024, 25: 732. PMID: 39478608, PMCID: PMC11523597, DOI: 10.1186/s13063-024-08404-2.Peer-Reviewed Original ResearchConceptsIntra-cluster correlation coefficientIntra-cluster correlation coefficient estimationSample size calculationED visitsMedicare dataMedicare fee-for-service beneficiariesEmergency departmentFee-for-service beneficiariesSize calculationDiagnosis of ADRDNational Medicare dataCluster randomized trialHospital referral regionsHospital service areasHealth care systemBackgroundCluster randomized trialsPopulation-level dataRandomized trialsDesign of cluster randomized trialsEvaluate interventionsReferral regionsCare systemICC estimatesADRDCorrelation coefficientPatient Priorities–Aligned Care for Older Adults With Multiple Conditions
Tinetti M, Hashmi A, Ng H, Doyle M, Goto T, Esterson J, Naik A, Dindo L, Li F. Patient Priorities–Aligned Care for Older Adults With Multiple Conditions. JAMA Network Open 2024, 7: e2352666. PMID: 38261319, PMCID: PMC10807252, DOI: 10.1001/jamanetworkopen.2023.52666.Peer-Reviewed Original ResearchConceptsPatient Priorities CarePatient-Reported Outcomes Measurement Information SystemPerceived treatment burdenUsual careUC participantsOutcomes Measurement Information SystemPatients' health prioritiesTreatment burden scoresHealth outcome goalsHealth care preferencesMeasurement Information SystemTreatment burdenDecision quality measuresPrescribing decision-makingFollow-upNonrandomized controlled trialsPatient-reported outcomesAlign careCare preferencesPriority careMultisite practiceHealth professionalsHealth priorityChronic conditionsSocial roles
2023
A mixed model approach to estimate the survivor average causal effect in cluster‐randomized trials
Wang W, Tong G, Hirani S, Newman S, Halpern S, Small D, Li F, Harhay M. A mixed model approach to estimate the survivor average causal effect in cluster‐randomized trials. Statistics In Medicine 2023, 43: 16-33. PMID: 37985966, DOI: 10.1002/sim.9939.Peer-Reviewed Original ResearchA Bayesian Approach for Estimating the Survivor Average Causal Effect When Outcomes Are Truncated by Death in Cluster-Randomized Trials
Tong G, Li F, Chen X, Hirani S, Newman S, Wang W, Harhay M. A Bayesian Approach for Estimating the Survivor Average Causal Effect When Outcomes Are Truncated by Death in Cluster-Randomized Trials. American Journal Of Epidemiology 2023, 192: 1006-1015. PMID: 36799630, PMCID: PMC10236525, DOI: 10.1093/aje/kwad038.Peer-Reviewed Original Research
2021
Accounting for unequal cluster sizes in designing cluster randomized trials to detect treatment effect heterogeneity
Tong G, Esserman D, Li F. Accounting for unequal cluster sizes in designing cluster randomized trials to detect treatment effect heterogeneity. Statistics In Medicine 2021, 41: 1376-1396. PMID: 34923655, PMCID: PMC10197222, DOI: 10.1002/sim.9283.Peer-Reviewed Original ResearchAssessment of Acute Kidney Injury and Longitudinal Kidney Function After Hospital Discharge Among Patients With and Without COVID-19
Nugent J, Aklilu A, Yamamoto Y, Simonov M, Li F, Biswas A, Ghazi L, Greenberg J, Mansour S, Moledina D, Wilson FP. Assessment of Acute Kidney Injury and Longitudinal Kidney Function After Hospital Discharge Among Patients With and Without COVID-19. JAMA Network Open 2021, 4: e211095. PMID: 33688965, PMCID: PMC7948062, DOI: 10.1001/jamanetworkopen.2021.1095.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedAged, 80 and overBlack or African AmericanCohort StudiesComorbidityCOVID-19CreatinineFemaleFollow-Up StudiesGlomerular Filtration RateHispanic or LatinoHumansHypertensionKidney Function TestsLongitudinal StudiesMaleMiddle AgedPatient DischargeProportional Hazards ModelsRenal Insufficiency, ChronicRetrospective StudiesSARS-CoV-2United StatesConceptsCOVID-19-associated acute kidney injuryAcute kidney injuryHospital acute kidney injurySubgroup of patientsKidney functionKidney injuryCohort studyHospital dischargeAKI recoveryKidney diseaseCOVID-19Peak creatinine levelsRetrospective cohort studyChronic kidney diseaseDays of dischargeHalf of patientsGlomerular filtration rateCoronavirus disease 2019AKI severityBaseline comorbiditiesEGFR decreaseDialysis requirementEGFR slopeKidney recoveryCreatinine levelsElectronic health record alerts for acute kidney injury: multicenter, randomized clinical trial
Wilson FP, Martin M, Yamamoto Y, Partridge C, Moreira E, Arora T, Biswas A, Feldman H, Garg AX, Greenberg JH, Hinchcliff M, Latham S, Li F, Lin H, Mansour SG, Moledina DG, Palevsky PM, Parikh CR, Simonov M, Testani J, Ugwuowo U. Electronic health record alerts for acute kidney injury: multicenter, randomized clinical trial. The BMJ 2021, 372: m4786. PMID: 33461986, PMCID: PMC8034420, DOI: 10.1136/bmj.m4786.Peer-Reviewed Original ResearchConceptsAcute kidney injuryElectronic health record alertsKidney injuryPrimary outcomeMedical recordsYale New Haven Health SystemCare practicesGlobal Outcomes creatinine criteriaLarge tertiary care centerComposite of progressionDays of randomizationReceipt of dialysisPrespecified secondary outcomesTertiary care centerPatients' medical recordsSmall community hospitalNon-teaching hospitalsElectronic health recordsCreatinine criteriaUsual careSecondary outcomesAdult inpatientsKidney diseaseClinical centersWorse outcomes
2017
Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study
Assel MJ, Li F, Wang Y, Allen AS, Baggerly KA, Vickers AJ. Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study. Ophthalmology 2017, 125: 391-397. PMID: 29032853, PMCID: PMC5820191, DOI: 10.1016/j.ophtha.2017.09.008.Peer-Reviewed Original ResearchConceptsAge-related macular degenerationAdvanced age-related macular degenerationEye Disease StudyGenotype-treatment interactionDisease StudyHigh-risk patientsStandard careAMD progressionBaseline predictorsMacular degenerationTreatment responseGenotype subgroupsAREDS participantsPatientsGenetic polymorphismsSingle nucleotide polymorphismsCategory 1Negative resultsAgePopulation of interestTreatmentMultiple testingProgressionNucleotide polymorphismsAntioxidants